After the sudden drop of MNKD which brought my attention to Afrezza, I can't stop following it's speculative news over the Stocktwits. I've blog about it previously, which I think this product is great. Licensing this product to Sanofi is probably the worst decision Alfred Mann could make. I still couldn't explain why an experienced entrepenuer who have so many succesful businesses in the past could make such a mistake.
May be it is not a mistake after all. Without such significant drop, the company and the product might not get such great attention. I myself get to know this product after the huge slump. Their patents are really valuable enough for Sanofi to kill it while it still young.
As a person who understand diabetes, no one will deny this product is great. I have a diabetic dad, and have met lots of aunties uncles with diabetes. The fact is, non of them likes to poke themselves with needles. Especailly they are old and clumsy and accident prone! Therefore, Afrezza should be the best alternative. Unfortunately it is not available in my country. Which is sad.
Marketing a pharmaceutical product can never be easy. I did understand that there's rules and regulations in different countries. Therefore I totally understand why MannKind need Sanofi to reach into the market. Unfortunately, Sanofi is the worst choice! Why not negotiate a deal with Pfizer, or Novartis... etc. May be they had done that, but still, working togather with the biggest competitor is not a wise idea.
So what's next for MannKind? Probably the best action is to retail Afrezza! Make it widely known or may be work togather with retail drugstores. I strongly believe this product is great. D*mn, if I have the money I will offer to buy over their patents. LOL.
Stange Things Happened!
Stange Things Happened!
I just realized a strange thing happened yesterday after the trading hours. Some strange Rich Man/Woman/Robot could have bought 600k unit of MNKD with $1.4543. Which is totally unexplainable. May be it is a plot to boost the market price.
No comments:
Post a Comment